Business Trends
Mega-Merger Talks Weigh on AstraZeneca as Bristol Myers Deal Raises Strategic Questions
Reports that AstraZeneca and Bristol Myers Squibb have discussed a nearly $400 billion merger sent AstraZeneca shares sharply lower as investors questioned the strategic rationale, regulatory hurdles, and potential impact on future drug development.